Senegal

Senegal is rapidly transforming into a premier destination for pharmaceutical manufacturing and biotechnology innovation in Africa, anchored by the world-class Institut Pasteur de Dakar (IPD).

The nation is best known for the landmark MADIBA project (Manufacturing in Africa for Disease Immunization and Building Autonomy), a state-of-the-art facility designed to achieve vaccine sovereignty through the large-scale production of COVID-19, yellow fever and endemic disease vaccines.

Beyond biologics, Senegal’s healthcare ecosystem is fueled by the Diamniadio Industrial Park, which attracts global medical device manufacturers and healthtech startups looking for a strategic entry point into the West African market.

The country’s regulatory environment is evolving quickly, with the Senegalese Agency for Pharmaceutical Regulation (ARP) working toward WHO maturity levels to streamline clinical trials and drug approvals.

Academic research excellence is centered at Université Cheikh Anta Diop (UCAD), a leading institution for infectious disease research and genomic surveillance.

Furthermore, Senegal is a pioneer in healthcare innovation, leveraging digital health solutions and telemedicine to bridge the gap in rural care delivery.

By fostering public-private partnerships (PPPs) and investing in biomanufacturing workforce training, Senegal is positioning itself as a resilient life sciences hub capable of addressing both regional and global health security.

The integration of precision medicine and cold-chain logistics infrastructure ensures that the nation remains at the forefront of the African pharmaceutical market expansion.

As a gateway to the ECOWAS region, Senegal offers an unparalleled environment for biopharma investment and collaborative R&D.